News from Zyme and the companies we work with.
Bio-Rad Launches Validated Antibodies for Rare Cell and Circulating Tumor Cell Enumeration
Antibodies Validated for Use with Bio-Rad’s Celselect Slides™ Enumeration Stain Kits to Enable Immunostaining of Captured Circulating Tumor Cells in Liquid Biopsy Samples HERCULES, Calif. — March 26, 2024 — [...]
Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration
Patent CN201380038920.6 upheld in response to invalidation challenge Dublin, Ireland, 26 March 2024: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned [...]
Teva UK and Closed Loop Medicine announce strategic partnership to advance development of personalised medicines
Castleford and London, UK, 26th March 2024: Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicine. Under the agreement, [...]
Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432
Project will be a demonstration of how Ubiquigent’s DUB-centric platform can support the development of DUB inhibitors all the way from discovery through to clinical development. Dundee, UK, and Lausanne, [...]
ArgusEye introduces AugaOne to accelerate downstream bioprocess development
AugaOne sensor system provides specific, real-time, and automated data to reduce mAb process development time New sensor will be exhibited at the Bioprocessing Summit, 18-21 March 2024, booth 66 Linköping, [...]
SolasCure Awarded £405K Innovate UK Biomedical Catalyst Grant to Advance Chronic Wound Care
Funding will be used to further optimize Aurase Wound Gel for future clinical trials SolasCure aims to deliver the first efficacious, cost-effective, and pain-free solution for millions of patients suffering [...]
Semarion introduces SemaCyte Multiplexing Platform to enhance cell assay data quality and speed during drug discovery
Expansion to SemaCyte Microcarrier platform enables optical barcoding and pooling of adherent cells to augment drug discovery high-content imaging and other screening processes Access available through Semarion’s Early Adopter Program [...]
Nuclera Joins Tech Nation’s Future Fifty Program
Nuclera recognized as one of UK’s most exciting growth stage companies Official launch of 2024 cohort taken place at 10 Downing Street Cambridge, UK, 19 March 2024: Nuclera, the biotechnology [...]
Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapies
Arrayjet’s patented spot-on-spot microarray screening technology is available for customers to adopt in-house and via Arrayjet’s CRO/CMO services Immunome signs deal to use Arrayjet platform in its in-house screening operations [...]
Nuclera appoints Joseph Bertelsen as Chief Commercial Officer
Key appointment to lead global commercial launch of eProtein Discovery platform Cambridge, UK, 14 March 2024: Nuclera, the biotechnology company enabling rapid protein expression and purification screening through its benchtop [...]
Ricoh and ERS Genomics enter into CRISPR/Cas9 license agreement
CRISPR/Cas9 genome editing technology contributes to the expansion of the creation of novel disease model Tokyo, Japan, and Dublin, Ireland, March 13, 2024: Ricoh Company, Ltd. today announced a non-exclusive [...]
Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation
Exploristics’ cloud-based simulation platform KerusCloud used to enhance study design for Exonate’s upcoming Phase IIb study following successful Phase Ib/IIa study Cambridgeshire and Belfast, UK, 12 March 2024: Exploristics, a [...]